FMPV 1
Alternative Names: FMPV-1Latest Information Update: 04 Oct 2023
At a glance
- Originator Hubro Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Colorectal cancer
- Preclinical Gastric cancer
Most Recent Events
- 30 Jun 2023 Hubro Therapeutics completes a phase-I trial in Colorectal cancer (In volunteers) in United Kingdom (Intradermal) (NCT05238558)
- 31 Jan 2022 Phase-I clinical trials in Colorectal cancer (In volunteers) in United Kingdom (Intradermal) (NCT05238558)
- 02 Dec 2021 Preclinical trials in Colorectal cancer (Prevention) in Norway (Intradermal) before December 2021 (Hubro Therapeutics pipeline, December 2021)